Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized crossover trial of sublingual APL-130277 versus subcutaneous apomorphine for OFF episodes in Parkinson's disease
2016-003456-70Phase 3Unknown
- Sponsor
- Sunovion
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of apomorphine in Parkinson's disease (PD) (2 arms), sponsored by Sunovion. Primary endpoint: Change in MDS-UPDRS Part III score. Status: unknown.
02
Drugs
apomorphine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2016-003456-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003456-70.